Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1133.67
HEB's Cash to Debt is ranked higher than
56% of the 831 Companies
in the Global Biotechnology industry.

( Industry Median: 56.93 vs. HEB: 1133.67 )
Ranked among companies with meaningful Cash to Debt only.
HEB' s 10-Year Cash to Debt Range
Min: 2.31   Max: No Debt
Current: 1133.67

Equity to Asset 0.88
HEB's Equity to Asset is ranked higher than
78% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. HEB: 0.88 )
Ranked among companies with meaningful Equity to Asset only.
HEB' s 10-Year Equity to Asset Range
Min: 0.35   Max: 0.98
Current: 0.88

0.35
0.98
F-Score: 3
Z-Score: -5.66
M-Score: -3.29
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -12044.59
HEB's Operating margin (%) is ranked lower than
94% of the 650 Companies
in the Global Biotechnology industry.

( Industry Median: -76.18 vs. HEB: -12044.59 )
Ranked among companies with meaningful Operating margin (%) only.
HEB' s 10-Year Operating margin (%) Range
Min: -12138.52   Max: -886
Current: -12044.59

-12138.52
-886
Net-margin (%) -10865.61
HEB's Net-margin (%) is ranked lower than
93% of the 650 Companies
in the Global Biotechnology industry.

( Industry Median: -72.15 vs. HEB: -10865.61 )
Ranked among companies with meaningful Net-margin (%) only.
HEB' s 10-Year Net-margin (%) Range
Min: -10816.67   Max: -1085.28
Current: -10865.61

-10816.67
-1085.28
ROE (%) -61.06
HEB's ROE (%) is ranked lower than
70% of the 755 Companies
in the Global Biotechnology industry.

( Industry Median: -27.55 vs. HEB: -61.06 )
Ranked among companies with meaningful ROE (%) only.
HEB' s 10-Year ROE (%) Range
Min: -217.32   Max: -20.44
Current: -61.06

-217.32
-20.44
ROA (%) -53.50
HEB's ROA (%) is ranked lower than
73% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -23.43 vs. HEB: -53.50 )
Ranked among companies with meaningful ROA (%) only.
HEB' s 10-Year ROA (%) Range
Min: -143.93   Max: -18.36
Current: -53.5

-143.93
-18.36
ROC (Joel Greenblatt) (%) -158.22
HEB's ROC (Joel Greenblatt) (%) is ranked higher than
57% of the 806 Companies
in the Global Biotechnology industry.

( Industry Median: -358.68 vs. HEB: -158.22 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
HEB' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3200   Max: -143.23
Current: -158.22

-3200
-143.23
EBITDA Growth (3Y)(%) 14.50
HEB's EBITDA Growth (3Y)(%) is ranked higher than
70% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. HEB: 14.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
HEB' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -29.8   Max: 16.1
Current: 14.5

-29.8
16.1
EPS Growth (3Y)(%) 8.70
HEB's EPS Growth (3Y)(%) is ranked higher than
66% of the 410 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. HEB: 8.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
HEB' s 10-Year EPS Growth (3Y)(%) Range
Min: -39.1   Max: 19.7
Current: 8.7

-39.1
19.7
» HEB's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

HEB Guru Trades in Q1 2014

Jim Simons Sold Out
» More
Q3 2014

HEB Guru Trades in Q3 2014

Jim Simons 73,700 sh (New)
» More
Q4 2014

HEB Guru Trades in Q4 2014

Jim Simons 254,400 sh (+245.18%)
» More
Q1 2015

HEB Guru Trades in Q1 2015

Jim Simons 672,500 sh (+164.35%)
» More
» Details

Insider Trades

Latest Guru Trades with HEB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 1.78
HEB's Forward P/E is ranked higher than
98% of the 311 Companies
in the Global Biotechnology industry.

( Industry Median: 21.05 vs. HEB: 1.78 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 1.90
HEB's P/B is ranked higher than
83% of the 1029 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. HEB: 1.90 )
Ranked among companies with meaningful P/B only.
HEB' s 10-Year P/B Range
Min: 0.47   Max: 11.74
Current: 1.9

0.47
11.74
P/S 291.20
HEB's P/S is ranked lower than
97% of the 1029 Companies
in the Global Biotechnology industry.

( Industry Median: 12.17 vs. HEB: 291.20 )
Ranked among companies with meaningful P/S only.
HEB' s 10-Year P/S Range
Min: 0   Max: 290.6
Current: 291.2

0
290.6
Current Ratio 4.69
HEB's Current Ratio is ranked higher than
53% of the 806 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. HEB: 4.69 )
Ranked among companies with meaningful Current Ratio only.
HEB' s 10-Year Current Ratio Range
Min: 1.36   Max: 44.82
Current: 4.69

1.36
44.82
Quick Ratio 4.56
HEB's Quick Ratio is ranked higher than
54% of the 806 Companies
in the Global Biotechnology industry.

( Industry Median: 4.16 vs. HEB: 4.56 )
Ranked among companies with meaningful Quick Ratio only.
HEB' s 10-Year Quick Ratio Range
Min: 1.36   Max: 44.19
Current: 4.56

1.36
44.19
Days Inventory 26.95
HEB's Days Inventory is ranked higher than
85% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 116.85 vs. HEB: 26.95 )
Ranked among companies with meaningful Days Inventory only.
HEB' s 10-Year Days Inventory Range
Min: 67   Max: 1827.33
Current: 26.95

67
1827.33

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.80
HEB's Price/Net Cash is ranked higher than
81% of the 816 Companies
in the Global Biotechnology industry.

( Industry Median: 14.50 vs. HEB: 3.80 )
Ranked among companies with meaningful Price/Net Cash only.
HEB' s 10-Year Price/Net Cash Range
Min: 1.08   Max: 231.25
Current: 3.8

1.08
231.25
Price/Net Current Asset Value 3.80
HEB's Price/Net Current Asset Value is ranked higher than
82% of the 859 Companies
in the Global Biotechnology industry.

( Industry Median: 10.20 vs. HEB: 3.80 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
HEB' s 10-Year Price/Net Current Asset Value Range
Min: 1.03   Max: 231.25
Current: 3.8

1.03
231.25
Price/Tangible Book 1.90
HEB's Price/Tangible Book is ranked higher than
87% of the 1028 Companies
in the Global Biotechnology industry.

( Industry Median: 6.50 vs. HEB: 1.90 )
Ranked among companies with meaningful Price/Tangible Book only.
HEB' s 10-Year Price/Tangible Book Range
Min: 0.72   Max: 231.25
Current: 1.9

0.72
231.25
Earnings Yield (Greenblatt) -51.80
HEB's Earnings Yield (Greenblatt) is ranked lower than
93% of the 1028 Companies
in the Global Biotechnology industry.

( Industry Median: -6.70 vs. HEB: -51.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
HEB' s 10-Year Earnings Yield (Greenblatt) Range
Min: -51.8   Max: 122785.9
Current: -51.8

-51.8
122785.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:HXB.Germany, HEB.Switzerland,
Hemispherx Biopharma Inc is a Delaware Corporation founded in the early 1970s. The Company is a specialty pharmaceutical company. It is engaged in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. Since its inception, it has established a foundation of laboratory, pre-clinical and clinical data with respect to the development of natural interferon and nucleic acids to enhance the natural antiviral defense system of the human body and to aid the development of therapeutic products for the treatment of certain chronic diseases. The Company owns and operates a 43,000 sq. ft. manufacturing facility in New Brunswick, NJ that produces Alferon and Ampligen. The Company operates in one segment, which performs research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon. The Company's primary pharmaceutical product platform consists of its experimental compound, Ampligen, its FDA approved natural interferon product, Alferon N Injection and, its experimental liquid natural interferon for oral administration, Alferon LDO (Low Dose Oral). As of December 31, 2013, the Company had 25 patents. Its potential competitors are among the largest pharmaceutical companies in the world, are well known to the public and the medical community, and have substantially greater financial resources, product development, and manufacturing and marketing capabilities. The Company is subject to various federal, state and local laws, regulations and recommendations relating to such matters as safe working conditions, laboratory and manufacturing practices, the experimental use of animals and the use of and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with its research work.
» More Articles for HEB

Headlines

Articles On GuruFocus.com
Hemispherx Biopharma Inc Reports Operating Results (10-Q/A) Feb 14 2011 
Hemispherx Biopharma Inc Reports Operating Results (10-K/A) Feb 14 2011 
Hemispherx Biopharma Inc Reports Operating Results (10-Q/A) Feb 14 2011 
Hemispherx Biopharma Inc Reports Operating Results (10-Q/A) Feb 14 2011 
Hemispherx Biopharma Inc Reports Operating Results (10-Q) Nov 08 2010 
Weekly CEO Sells Highlight: Hemispherx Biopharma Inc, ADESA Inc, Entergy Corp, and Danaher Corp. Aug 15 2010 
Hemispherx Biopharma Inc Reports Operating Results (10-Q) Aug 06 2010 
Hemispherx Biopharma Inc (HEB) CEO William A Carter buys 500,000 Shares Jul 01 2010 
Weekly CFO Buys Highlight: Wireless Telecom Group, ValueVision Media, American River Bankshares, Hem Dec 12 2009 
Hemispherx Biopharma Inc (HEB) CFO Charles Thomas Iii Bernhardt buys 2,000 Shares Dec 08 2009 

More From Other Websites
Hemispherx Biopharma Europe N.V./S.A. : Orphan Medicine Designation and European Medicines Agency... May 26 2015
12:51 pm Hemispherx Biopharma announces the publication of the EMA's public opinion and record... May 26 2015
Hemispherx Biopharma Europe N.V./S.A.: Orphan Medicine Designation and European Medicines Agency... May 26 2015
HEMISPHERX BIOPHARMA INC Financials May 22 2015
Hemispherx to Present at the Marcum Microcap Conference in New York ….Planned Launch of Alferon N... May 20 2015
Hemispherx to Present at the Marcum Microcap Conference in New York May 20 2015
Pomerantz Law Firm Announces Summary Notice of Pendency and Proposed Settlement of Hemispherx... May 18 2015
10-Q for Hemispherx Biopharma, Inc. May 14 2015
Hemispherx Biopharma Announces Financial Results for the Three Months Ended March 31, 2015 May 13 2015
HEMISPHERX BIOPHARMA INC Files SEC form 10-Q, Quarterly Report May 12 2015
Hemispherx Biopharma Europe N.V./S.A. Receives Orphan Medicine Designation by the European Medicines... May 11 2015
Hemispherx Biopharma Europe N.V./S.A. Receives Orphan Medicine Designation by the European Medicines... May 11 2015
Pomerantz Law Firm Announces Summary Notice of Pendency and Proposed Settlement of Hemispherx... May 07 2015
4 Biotech Stocks Under $10 to Trade for Breakouts May 07 2015
10-K for Hemispherx Biopharma, Inc. May 02 2015
4 Stocks Under $10 Making Big Moves Higher Apr 30 2015
Midtown Partners & Co, LLC Initiates Coverage and Arrowhead b.i.d. Issues Coverage Update on... Apr 28 2015
Coverage initiated on Hemispherx Biopharma by Midtown Partners Apr 02 2015
Hemispherx Biopharma Europe N.V./S.A. Receives Positive Opinion on Application for Orphan... Mar 24 2015
Hemispherx Biopharma to Present Data on the Activity of Ampligen(R) Against the Ebola Virus Mar 23 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK